Multiple Myeloma: Possible Cure from the Sea.

Area of Science:

• Marine biology
• Pharmacology
• Oncology

Background:

• Multiple myeloma (MM) is a plasma cell blood cancer with limited curative treatment options.
• Current therapies extend survival but do not offer a cure for most patients.
• There is a significant need for novel therapeutic strategies against MM.

Purpose of the Study:

• To review the current landscape of multiple myeloma therapies.
• To highlight the emerging roles of marine natural products in MM treatment.
• To explore the potential of marine-derived compounds as anticancer agents.

Main Methods:

• Literature review of existing studies on marine natural products and MM.
• Analysis of preclinical and clinical trial data for marine-derived drugs.
• Identification of key marine compounds and their mechanisms of action.

Main Results:

• Several marine-derived drugs, such as BLENREP™ and Aplidin®, are approved for MM treatment.
• Other marine compounds, including cytarabine, are in various stages of clinical trials.
• Successful marine compounds target specific pathways like elongation factor 1-alpha 2 and proteasomes, or are antibody conjugates.

Conclusions:

• Marine organisms are a rich source of diverse chemical compounds with potent anticancer activities.
• Marine natural products represent a promising avenue for developing innovative MM therapies.
• Continued screening and development of these compounds could lead to more effective treatments for multiple myeloma.